FDAsafety guidance72% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (lung cancer) as Bristol Myers Squibb.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Non-Small Cell Lung Cancer
- Sub-indication
- Lung Cancer
Related signal: Bristol-Myers Squibb Evaluates Pumitamig vs Pembrolizumab in NSCLC Trial